ORPHA:168829
Primary peritoneal carcinoma
Also known as: EOPPC · Extra-ovarian primary peritoneal carcinoma · PPC · Primary peritoneal serous carcinoma · Serous surface papillary carcinoma
Publications
4,812
Trials
536
Interventional, condition-specific
Researchers
1,350
Distinct authors in sample
Gene link
—
Readiness
4/6
Stages with a signal
Clinical definition (Orphanet)
Primary peritoneal carcinoma (PPC) is a rare malignant tumor of the peritoneal cavity of extra-ovarian origin, clinically and histologically similar to advanced-stage serous ovarian carcinoma.
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0015686
- UMLS:C1514428
- NCIT:C40022
Additional Mondo synonyms (5)
primary peritoneal cancer · primary peritoneal carcinoma · primary peritoneal carcinoma (disease) · primary peritoneal serous carcinoma · serous surface papillary carcinoma
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
4/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
4,812 matched papers (3,329 in last 10 years) Source
- Phenotype characterisedPresent
6 HPO annotations (e.g. Nausea and vomiting; Constipation; Peritonitis) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationPresent
3 FDA · 1 EMA designations (1 FDA orphan-indication approval) — e.g. pelareorep Source
- Interventional trialPresent
536 matched on ClinicalTrials.gov (73 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
6
Associated phenotypes · MONDO:0015686
- Nausea and vomiting
- Constipation
- Peritonitis
- Neoplasm
- Abdominal distention
Showing 5 of 6 — open Monarch for the full list.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
4
Designations · 1 with FDA orphan-indication approval
- FDA pelareorepPrimary Peritoneal Cancer · 2015-02-24 · Not FDA Approved for Orphan Indication
- FDA olaparib (Lynparza)Primary Peritoneal Cancer · 2018-05-15
- FDA bevacizumab (Avastin)Primary peritoneal carcinoma · 2010-11-02
- EMA patupiloneTreatment of primary peritoneal cancer · 05/11/2009 · WithdrawnEMA designation
Sources: FDA OOPD · EMA orphan designations
Open Targets candidates
252
Drugs / clinical candidates · MONDO_0015686
- ATEZOLIZUMAB·phase 3
- AVELUMAB·phase 3
- AZENOSERTIB·phase 3
- BEVACIZUMAB·phase 3
- CANFOSFAMIDE·phase 3
- CANFOSFAMIDE HYDROCHLORIDE·phase 3
- CARBOPLATIN·phase 3
- CATEQUENTINIB·phase 3
- CEDIRANIB·phase 3
- CISPLATIN·phase 3
- CYCLOPHOSPHAMIDE·phase 3
- DOCETAXEL·phase 3
- DOSTARLIMAB·phase 3
- DOXORUBICIN·phase 3
- DOXORUBICIN HYDROCHLORIDE·phase 3
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
4,812
4,812 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
4,812 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
3,329 in the last 10 years · low confidence
Phrase hits: 4,812 · MeSH hits: 0
Who's working on it?
1,350
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Aida T4 papers · 2026
Department of Obstetrics and Gynecology, Hachinohe Red Cross Hospital, Aomori 039-1104, Japan.
Papers in Europe PMC - 02Baba T4 papers · 2026
Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, Yahaba 028-3695, Japan.
Papers in Europe PMC - 03Chiba Y4 papers · 2026
Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, Yahaba 028-3695, Japan.
Papers in Europe PMC - 04Jo A4 papers · 2026
Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, Yahaba 028-3695, Japan.
Papers in Europe PMC - 05Jonai N4 papers · 2026
Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, Yahaba 028-3695, Japan.
Papers in Europe PMC - 06Kagabu M4 papers · 2026
Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, Yahaba 028-3695, Japan.
Papers in Europe PMC - 07Kaido Y4 papers · 2026
Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, Yahaba 028-3695, Japan.
Papers in Europe PMC - 08Mądry R4 papers · 2025
Oncological Gynaecology Department, Poznan University of Medical Sciences, 60-569 Poznań, Poland.
Papers in Europe PMC - 09Nagasawa T4 papers · 2026
Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, Yahaba 028-3695, Japan.
Papers in Europe PMC - 10Sato S4 papers · 2026
Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, Yahaba 028-3695, Japan.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
536
interventional trials for this specific condition
536 interventional trials matched this specific condition name; 73 currently recruiting in our sample. 30 trials are registered for peritoneal carcinoma, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 11 September 2026
536 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 99.7th percentile).
low confidence · 99.7th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
536 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT05128825·RECRUITING·A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Not reviewed·Conditions: High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer·Matched via name phrase
- NCT05659381·RECRUITING·Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Not reviewed·Conditions: Stage III Ovarian Cancer · Stage IV Ovarian Cancer · Stage III Primary Peritoneal Cancer · Stage IV Primary Peritoneal Cancer·Matched via name phrase
- NCT07674615·NOT YET RECRUITING·IMMU-132 in TROP-2 Overexpressed Advanced and Relapsed Ovarian Cancer
Not reviewed·Conditions: Epithelial Ovarian Cancer · Fallopian Tube Cancers · Primary · Primary Peritoneal Carcinoma·Matched via name phrase
- NCT07480954·RECRUITING·Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)
Not reviewed·Conditions: Epithelial Ovarian Cancer · Primary Peritoneal Carcinoma · Fallopian Tube Carcinoma · Recurrent or Refractory Disease After Standard Therapies·Matched via name phrase
- NCT07044349·NOT YET RECRUITING·Phase II Clinical Study of Utidelone Capsule (UTD2) in Patients With Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Not reviewed·Conditions: Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Cancer·Matched via name phrase
- NCT07532148·NOT YET RECRUITING·Study of CKD-215 and D215 in Adults With BRCA-mutated Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Not reviewed·Conditions: Ovarian Cancer·Matched via name phrase
- NCT04575935·RECRUITING·Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
Not reviewed·Conditions: Advanced Ovarian Carcinoma · Fallopian Tube Clear Cell Adenocarcinoma · Fallopian Tube Endometrioid Tumor · Fallopian Tube Serous Neoplasm·Matched via name phrase
- NCT05092373·RECRUITING·Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
Not reviewed·Conditions: Advanced Breast Carcinoma · Advanced Endometrial Carcinoma · Advanced Fallopian Tube Carcinoma · Advanced Hepatocellular Carcinoma·Matched via name phrase
- NCT06855706·RECRUITING·An Automated Personalized Physical Activity Intervention to Improve Immune Function and Clinical Outcomes in Stage II-IV Ovarian, Primary Peritoneal or Fallopian Tube Cancer and Newly Diagnosed Endometrial Cancer, Life on the Go 3 Study
Not reviewed·Conditions: Endometrial Carcinoma · Recurrent Fallopian Tube Carcinoma · Recurrent Ovarian Carcinoma · Recurrent Primary Peritoneal Carcinoma·Matched via name phrase
- NCT02637934·RECRUITING·Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Not reviewed·Conditions: Suspected Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer·Matched via name phrase
- NCT03604315·RECRUITING·Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF
Not reviewed·Conditions: Breast Carcinoma · Fallopian Tube Carcinoma · Ovarian Carcinoma · Primary Peritoneal Carcinoma·Matched via name phrase
- NCT07322094·RECRUITING·CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer
Not reviewed·Conditions: FIGO Stage III and IV Ovarian Cancer · Fallopian Tube Cancers · Primary Peritoneal Cancer·Matched via name phrase
- NCT05564377·RECRUITING·Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Not reviewed·Conditions: Advanced Malignant Solid Neoplasm · Anatomic Stage III Breast Cancer AJCC v8 · Anatomic Stage IV Breast Cancer AJCC v8 · Locally Advanced Malignant Solid Neoplasm·Matched via name phrase
- NCT05281471·RECRUITING·Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
Not reviewed·Conditions: Platinum-resistant Ovarian Cancer · Platinum-refractory Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Cancer·Matched via name phrase
- NCT05737303·RECRUITING·Nab-paclitaxel Versus Sb-taxanes As First-Line Treatment in Advanced Ovarian Cancer
Not reviewed·Conditions: Epithelial Ovarian Carcinoma Stage III · Epithelial Ovarian Carcinoma Stage IV · Fallopian Tube Carcinoma Stage III · Fallopian Tube Carcinoma Stage IV·Matched via name phrase
Broader category: peritoneal carcinoma
30
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT06290193·RECRUITING·Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surgery
Not reviewed·Conditions: Ovarian Cancer · Fallopian Tube Carcinoma · Ovarian Carcinoma · Peritoneal Carcinoma·Matched via name phrase
- NCT06846424·NOT YET RECRUITING·SCT-001 CAR T Cells Therapy for Relapsed and Refractory Ovarian Cancer
Not reviewed·Conditions: Ovarian Cancer · Fallopian Tube Carcinoma · Peritoneal Carcinoma·Matched via name phrase
- NCT06743867·RECRUITING·The Safety and Efficacy of Pressurized Intraperitoneal Aerosol Chemotherapy for Peritoneal Metastatic Adenocarcinoma
Not reviewed·Conditions: Peritoneal Carcinoma Metastatic·Matched via name phrase
- NCT04684459·RECRUITING·Dual-targeting HER2 and PD-L1 CAR-T for Solid Tumors
Not reviewed·Conditions: Peritoneal Carcinoma Metastatic · Pleural Effusion, Malignant · HER2 Positive Malignancies·Matched via name phrase
- NCT07001592·RECRUITING·Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors
Not reviewed·Conditions: Gastric Neoplasms · Esophageal Cancer · Liver Cancer · Liver Metastasis·Matched via name phrase
Observational and natural-history studies
44 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT06295965·RECRUITING·Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers, CHANCES Study
Not reviewed·Conditions: Recurrent Fallopian Tube Carcinoma · Recurrent Ovarian Carcinoma · Recurrent Primary Peritoneal Carcinoma · Recurrent Malignant Solid Neoplasm·Matched via name phrase
- NCT07667192·RECRUITING·Reirradiation and Total Ablative Strategies for Recurrent Gynecologic Cancer
Not reviewed·Conditions: Recurrent Gynecologic Cancer · Recurrent Uterine Cancer · Recurrent Cervical Cancer · Recurrent Vaginal Cancer·Matched via name phrase
- NCT05574673·RECRUITING·Characterization of Epithelial Ovarian Cancer Patients in Terms of Homologous Recombination Phenotype
Not reviewed·Conditions: Ovarian Cancer · Primary Peritoneal Cancer · Fallopian Tube Cancer·Matched via name phrase
- NCT07269574·NOT YET RECRUITING·Impact of Dietary Patterns on Prognosis of Ovarian Cancer Patients During PARPi Maintenance
Not reviewed·Conditions: Ovarian Cancer · Fallopian Tube Cancers · Primary Peritoneal Carcinoma · High-grade Serous Ovarian Cancer·Matched via name phrase
- NCT00488878·RECRUITING·Data Collection for Patients With Low Grade Ovarian or Peritoneal Tumors
Not reviewed·Conditions: Low Grade Ovarian Serous Adenocarcinoma · Malignant Ovarian Neoplasm · Ovarian Carcinoma · Primary Peritoneal Carcinoma·Matched via name phrase
- NCT07690332·NOT YET RECRUITING·A Real-world Study of Mirvetuximab Soravtansine (MIRV) in Ovarian Cancer Patients of Expression of Folate Receptor α(FRα)
Not reviewed·Conditions: Ovarian Cancer · Fallopian Tube Cancers · Primary Peritoneal Cancer·Matched via name phrase
- NCT06010667·NOT YET RECRUITING·A Prospective, Randomized Controlled Study of Cyclophosphamide, Bevacizumab With or Without Envafolimab in Recurrent Epithelial Ovarian Cancer (EOC), Fallopian Tube Cancer, and Primary Peritoneal Cancer
Not reviewed·Conditions: Epithelial Ovarian Cancer·Matched via name phrase
- NCT07407062·NOT YET RECRUITING·A Study to Evaluate Folate Receptor Alpha (FRα) Expression in Adult Participants With Ovarian, Fallopian Tube, and Primary Peritoneal Cancer in Italy
Not reviewed·Conditions: Cancer - Ovarian·Matched via name phrase
- NCT07687602·NOT YET RECRUITING·A Study to Evaluate Adverse Events and Change in Disease Activity of Mirvetuximab Soravtansine-gynx in Adults With Folate Receptor-Alpha Positive, Platinum-Resistant Ovarian Cancer in a Real-World Setting
Not reviewed·Conditions: Folate Receptor-Alpha Positive Platinum-Resistant High-Grade Serous Epithelial Ovarian Cancer · Folate Receptor-Alpha Positive Platinum-Resistant Fallopian Tube Cancer · Folate Receptor-Alpha Positive Platinum-Resistant Primary Peritoneal Cancer·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 43 · after dedupe 43 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 43 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (43)
- ctis·2024-511851-16-00·Cancelled·A phase 1 study to evaluate the dose, safety and tolerability of a radionuclide therapy (Radspherin®) in patients with platinum sensitive recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma with peritoneal carcinomatosis following complete surgical resection
skipped — LLM skipped (--skip-llm)
- ctis·2023-509150-64-00·Cancelled·NXP800 in subjects with Ovarian Cancer
skipped — LLM skipped (--skip-llm)
- ctis·2023-506177-35-00·Expired·A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Paclitaxel With or Without Bevacizumab for the Treatment of Platinum-resistant Recurrent Ovarian Cancer (KEYNOTE-B96 / ENGOT-ov65).
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN21041967·Recruiting·Description and study of the steroid Metabolome in mucinous ovarian cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN78284158·No longer recruiting·Heated intraperitoneal chemotherapy for the treatment of primary ovarian cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN48890983·Stopped·A study to test the effectiveness of a vaccine targeting a protein that hides cancer cells from the body's immune system in operable colorectal cancer that has defective mismatch repair
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN45104480·Recruiting·A modular, multi-part, multi-arm, open-label, phase I/II study to evaluate the safety and tolerability of GRWD5769 alone and in combination with anticancer treatments in patients with solid malignancies
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN14298588·No longer recruiting·A study to examine the effects of preoperative envafolimab and chemotherapy in advanced stomach and gastroesophageal junction cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN13282459·Recruiting·SOPRANO - Stereotactic radiotherapy alone or stereotactic radiotherapy follow by niraparib treatment for ovarian cancer with progressive disease in three or less lesions, or recurrence of 3 or less metastatic lesions that had previously achieved complete response.
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN17575409·Recruiting·Pressurised IntraPeritoneal Aerosolised Chemotherapy (PIPAC) in the management of cancers of the bowel, ovary and stomach: a randomised controlled trial of efficacy in peritoneal metastases
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN77394655·No longer recruiting·Study to determine the preventive effect of denosumab on breast cancer in women carrying a BRCA1 germline mutation
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN78740398·Recruiting·The first-in-human trial of MDX-124 in patients with advanced cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN12633596·No longer recruiting·A study to test mirvetuximab soravtansine in women with platinum sensitive, advanced epithelial ovarian, primary peritoneal, or fallopian tube cancers.
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN83842641·Recruiting·A trial assessing preoperative chemotherapy in patients with locally advanced but operable colon cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN62420110·No longer recruiting·A study of selicrelumab (RO7009789) in combination with atezolizumab in participants with locally advanced and/or metastatic solid tumors
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN45319897·No longer recruiting·A study to evaluate the safety, tolerability, processing by the body, and antitumor activity of inavolisib and paclitaxel
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN15067672·No longer recruiting·A randomised multicenter clinical trial for patients with multi-organ, colorectal cancer metastases comparing the combination of chemotherapy and removing as many visible tumors as possible by surgery or other means versus chemotherapy alone
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN25173360·Suspended·Early removal of Fallopian tubes and delayed removal of ovaries in women at high risk of ovarian cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN12206108·No longer recruiting·Oxaliplatin plus S-1 or capecitabine chemotherapy before or after surgery for locally advanced gastric cancer with D2 lymphadenectomy: a phase II-III randomized trial
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN10490346·No longer recruiting·An investigation of whether rucaparib is safe and more effective when combined with either one or two immunotherapy drugs (nivolumab and ipilimumab), when compared to rucaparib on its own
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN14784018·No longer recruiting·Trial of different drug and treatment combinations for patients who are considering further therapy to treat their ovarian cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN95351638·No longer recruiting·PRISM – A Phase II trial testing alternate schedules of combination Ipilimumab-Nivolumab therapy for patients with advanced and metastatic renal cell carcinoma
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN38690336·No longer recruiting·Is it safe to add cediranib to weekly paclitaxel chemotherapy in women with ovarian cancer who are at risk of developing malignant bowel obstruction?
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN89947480·No longer recruiting·PIPAC for peritoneal metastases of colorectal cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN16426935·No longer recruiting·OCTOPUS - ovarian cancer trials of weekly paclitaxel
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Primary peritoneal carcinoma — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Primary peritoneal carcinoma" OR "EOPPC" OR "Extra-ovarian primary peritoneal carcinoma" OR "Primary peritoneal serous carcinoma" OR "Serous surface papillary carcinoma" OR "primary peritoneal cancer" OR "primary peritoneal carcinoma (disease)"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Primary peritoneal carcinoma" OR "EOPPC" OR "Extra-ovarian primary peritoneal carcinoma" OR "Primary peritoneal serous carcinoma" OR "Serous surface papillary carcinoma" OR "primary peritoneal cancer" OR "primary peritoneal carcinoma (disease)"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 536 interventional · 44 observational · 1 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"peritoneal carcinoma"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: PPC
Confidence reasoning
- Preferred label is multi-word and distinctive
- 1 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
- Publication count (4812) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity
Ingested 2026-07-27T08:31:31.271Z
